An observational study in Dyslipidemias, sponsored by Vital Signs Solutions Ltd. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-17.
Sponsored by Vital Signs Solutions Ltd · Observational
This study seeks to improve access to lipid testing in out-of-surgery locations using PocDoc, a UKCA approved IVD device that measures a full 5 marker lipid panel using a smartphone or tablet. The study will investigate whether PocDoc can close the gap in people not tested by exploring 3 new out-of-surgery methods:
Lipid testing in out-of-surgery (OOS) locations using a digital lipid measuring device called PocDoc promises to increase access to lipid testing and cardiovascular disease health assessment. PocDoc lipids comprises a smartphone-compatible disposable microchip test strip which uses proprietary colorimetric microfluidic technology to accurately detect lipid biomarkers from a droplet of blood. PocDoc Lipids Professional was launched in 2022 to enable professional users to perform lipid screens as part of lifestyle or preventative healthcare screens. The investigator's hypothesise that providing easier, more cost-effective access to lipid testing at scale, without patients having to attend the GP surgery could:
The SBRI 21 Phase 3 program is funding this collaborative project in partnership with SMASH PCN and AHSN NENC with the objective of increasing access to lipid testing in those geographies.
1,101 studies on the registry are indexed under Dyslipidemias; 161 are open to participants now.
This study's enrollment of 4,256 is above the median of 600 across 212 observational studies indexed under Dyslipidemias.
Browse Dyslipidemias studies →Vital Signs Solutions Ltd is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Individuals in the primary prevention setting who have not previously had a cardiovascular event such as a heart attack or stroke as well as individuals in the secondary prevention setting who have had previous cardiovascular events.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
There are significant numbers of patients in primary care who should be given annual lipid checks who are not receiving them. PocDoc is a digital rapid 5-marker lipid panel that uses a smartphone as a diagnostic reader. PocDoc tests will be offered to patients overdue their annual lipid check either in surgery, in the community or in their own home.
Diagnostic Test: PocDoc
Providing lipid testing in community settings such as in pharmacy may offer a more attractive solution to consumers. This hypothesis will be tested by offering PocDoc lipid tests in a community setting.
Diagnostic Test: PocDoc
Providing lipid testing as part of a health wellness screen in employees workplaces in may offer an attractive solution to consumers needing their lipid levels check. This hypothesis will be tested by offering PocDoc lipid tests as part of corporate wellness screens.
Diagnostic Test: PocDoc
PocDoc is a digital rapid 5-marker lipid test
Overall response rate
Number and proportion of individuals contacted who conduct a PocDoc test
Time frame: Day 1 - one single test done at one timepoint
Achieved response rate
Number and proportion of individuals who conduct a PocDoc test that have dyslipidaemia
Time frame: Day 1 - one single test done at one timepoint
PocDoc experience
Number (N) and proportion (%) of individuals reporting a positive experience with the PocDoc testing pathway
Time frame: Day 1 - one single test done at one timepoint
PocDoc value
c. Number (N) and proportion (%) of individuals reporting improvements vs in surgery testing procedure with regards to convenience, speed of testing, testing process
Time frame: Day 1 - one single test done at one timepoint
Plan to share: No
Ran from Jun 2023 to primary completion in Sep 2024, 14 months.
Of 29 industry-sponsored observational studies under Dyslipidemias, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 14 months is below that.
Counting every sponsor, half of 81 studies reached it within 36 months; a quarter within 23 and three quarters within 118.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vital Signs Solutions Ltd